首页   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  • Wnt/Stem Cell
  • Epigenetics
  >  
JAK

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

JAK

结构式 货号 产品名称 CAS号
Ilginatinib 结构式
BCP44119 Ilginatinib 1239358-86-1
Ilginatinib is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. JAK2/Src inhibitor NS-018 competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, NS-018 inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis.
Aurora B inhibitor 1 结构式
BCP42843 Aurora B抑制剂1 937276-52-3
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
BD750 结构式
BCP42671 BD750 892686-59-8
BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively.
SB1317 结构式
BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
SHR0302 结构式
BCP34833 SHR0302 1445987-21-2
SHR0302 is a novel potent JAK inhibitor, blocking JAK/STAT3 signaling, suppressing proliferation, migration and collagen production, and inducing the apoptosis of hepatic stellate cells.
Deuruxolitinib 结构式
BCP36774 Deuruxolitinib 1513883-39-0
AZD-4205 结构式
BCP36112 AZD-4205 2091134-68-6
AZD4205 is a novel potent and selective janus kinase 1 (JAK1) inhibitor.
Gusacitinib hydrochloride 结构式
BCP35707 Gusacitinib hydrochloride 2228989-14-6
Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM.
TG-89 结构式
BCP35054 TG-89 936091-56-4
TG-89 is an inhibitor of JAK2, FLT3, RET and JAK3.
Delgocitinib 结构式
BCP34832 迪高替尼 1263774-59-9
Delgocitinib is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
123下一页末页共 82 条记录 1 / 9 页 
2853530913